Latest pediatric asthma Stories
GENEVA and ZURICH, June 19, 2012 /PRNewswire/ -- - AAAAI, ACAAI, EAACI and WAO launch the International Consensus (ICON) on Pediatric Asthma at the EAACI Congress 2012 - The goal of the Pediatric Asthma ICON is to ensure appropriate asthma management to control the disease and improve the quality of life of patients. - The Pediatric Asthma ICON is part of the iCAALL initiative, International Collaboration in Asthma, Allergy and Immunology. The...
The CareSource Foundation, part of CareSource, a non-profit, public-sector managed care company, recently announced a $75,000 Signature Grant to the Ohio Chapter of the American Academy of Pediatrics for a high-impact, statewide children's asthma pilot project. Dayton, OH (Vocus) November 9, 2010 The CareSource Foundation, part of CareSource, a non-profit, public-sector managed care company, recently announced a $75,000 Signature Grant to the Ohio Chapter of the American Academy of...
ATLANTA, March 1 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), a leading provider of clinical information and medication delivery technologies, today announced that Memorial Healthcare System (MHS) was honored as a finalist in the HIMSS (Healthcare Information and Management Systems Society) inaugural "Stories of Success! Leveraging HIT, Improving Quality & Safety" program. Memorial Healthcare System of South Florida, one of 16 applicants selected for recognition, used Hospira's...
Hypnosis has potential therapeutic value in children with respiratory disorders for alleviating symptoms such as habit cough or unexplained sensations of difficulty breathing and for lessening a child's discomfort during medical procedures. Proper utilization of hypnosis as an adjunct to conventional treatment and its ability to use the mind-body connection to bring about physiological changes are explored in a provocative paper in Pediatric Asthma, Allergy & Immunology, a peer-reviewed...
LONDON and MOUNTAIN VIEW, Calif., Dec. 19 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) and MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced today an exclusive worldwide agreement to develop and commercialize Unit Dose Budesonide (UDB), MAP Pharmaceuticals' proprietary nebulized formulation of budesonide. UDB is being developed by MAP Pharmaceuticals as a potential treatment for pediatric asthma and is currently in Phase III clinical development. UDB has the potential to be...
MOUNTAIN VIEW, Calif., Sept. 22 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. today announced that it has completed patient enrollment in its Phase 3 clinical trial evaluating Unit Dose Budesonide (UDB), the company's proprietary nebulized version of budesonide, for the potential treatment of pediatric asthma. The purpose of the Phase 3 trial is to evaluate the safety and efficacy of UDB as a potential treatment of pediatric asthma in approximately 360 children from 12 months to...
By Fiese, Barbara Winter, Marcia; Anbar, Ran; Howell, Kimberly; Poltrock, Scott This preliminary report links the literatures on family asthma management practices and on the characteristics of family interaction patterns thought to influence children's adjustment to a chronic physical illness. Specifically, this study of 60 families with a child with asthma examined the extent to which perceived burden of routine asthma care affected child mental health via its influence on parent-child...
